Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation

被引：37

作者：

Tomioka, Atsushi ^{[2
]}

Tanaka, Motoyoshi ^{[1
]}

De Velasco, Marco A. ^{[1
]}

Anai, Satoshi ^{[2
]}

Takada, Satoshi ^{[2
]}

Kushibiki, Toshihiro ^{[3
]}

Tabata, Yasuhiko ^{[3
]}

Rosser, Charles J. ^{[4
]}

Uemura, Hirotsugu ^{[1
]}

Hirao, Yoshihiko ^{[2
]}

机构：

[1] Kinki Univ, Sch Med, Dept Urol, Sayama, Osaka 5898511, Japan

[2] Nara Med Univ, Dept Urol, Nara, Japan

[3] Kyoto Univ, Dept Biomat Field Tissue Engn, Kyoto, Japan

[4] Univ Florida, Dept Urol, Gainesville, FL USA

来源：

MOLECULAR CANCER THERAPEUTICS | 2008年 / 7卷 / 07期

关键词：

D O I：

10.1158/1535-7163.MCT-07-2198

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The tumor suppressor gene MMAC/PTEN located on chromosome 10q23.3 has dual phosphatase activity in the phosphoinositide-3-kinase signaling pathway and inhibits Akt activation, a serine-threonine kinase, which is involved in proliferative and antiapoptotic pathways. Furthermore, MMAC/PTEN is frequently inactivated in a variety of tumors including prostate cancer. In this study we generated a new type of gene transfer drug, GelaTen: which is a microsphere of cationized gelatin hydrogels incorporating PTEN plasmid DNA. Using our previously reported radiation-resistant PC3-Bcl-2 human prostate cancer cells (PTEN deleted), we examined the efficacy of GelaTen to force the expression of PTEN in vivo to inhibit tumor growth after intratumoral injection alone or with irradiation. Combinational therapy with GelaTen and irradiation improved both the in vitro and in vivo efficacy of growth inhibition compared with GelaTen or irradiation alone. These data show that GelaTen gene therapy, enabling radiosensitization, can potentially treat prostate cancers that have MMAC/PTEN gene alterations associated with radioresistance.

引用

页码：1864 / 1870

页数：7

共 37 条

[1]

Cairns P, 1997, CANCER RES, V57, P4997

[2] New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase AKT pathway [J].